31 July 2017
Syncona
Limited
2017 dividend
scrip reference price
The Board of Syncona Limited (the "Company") announces that the
scrip reference price for the Company’s 2017 dividend will be
£1.7184. This is the higher of (i) the prevailing average of
the middle market quotations of the Shares derived from the Daily
Official List of the London Stock Exchange for the ex-dividend
date, 20 July 2017, and the four
subsequent dealing days and (ii) the net asset value per Share of
the Company as at 30 June 2017.
[ENDS]
Enquiries
Northern Trust International Fund Administration Services
(Guernsey) Limited
Company Secretary
Tel: 01481 745001
Copies of this announcement and other corporate information can
be found on the company website at:www.synconaltd.com
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on
investing in and building global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders. Our current investment portfolio consists
of seven high quality companies in life science and a leading range
of fund investments.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses. We are
established leaders in gene therapy, cell therapy and advanced
diagnostics, and focus on delivering dramatic efficacy for patients
in areas of high unmet need.
Our market leading funds portfolio seeks to generate superior
returns by investing in long only and alternative investment funds.
This represents a productively deployed evergreen funding base
which enables us to take a long term approach to investing in life
sciences as we target the best new opportunities and support our
existing portfolio companies to grow and succeed.
Syncona is aligned with two of the premium charitable funders in
UK science, the Wellcome Trust, original founder of Syncona, and
Cancer Research UK, both of which are significant shareholders in
our business. We make a donation of 0.3% of Net Asset Value
to a range of charities each year.